X/T + X-EC + Placebo + Lecanemab 10 mg/kg
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alzheimers Disease
Conditions
Alzheimers Disease
Trial Timeline
Dec 1, 2025 → Dec 30, 2028
NCT ID
NCT07212062About X/T + X-EC + Placebo + Lecanemab 10 mg/kg
X/T + X-EC + Placebo + Lecanemab 10 mg/kg is a phase 2 stage product being developed by Bristol Myers Squibb for Alzheimers Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07212062. Target conditions include Alzheimers Disease.
What happened to similar drugs?
0 of 5 similar drugs in Alzheimers Disease were approved
Approved (0) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07212062 | Phase 2 | Recruiting |
Competing Products
15 competing products in Alzheimers Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E2814 + Lecanemab + Matching Placebo (E2814) | Eisai | Phase 2/3 | 42 |
| Gantenerumab + Solanezumab + Matching Placebo (Gantenerumab) + Matching Placebo (Solanezumab) + Gantenerumab + E2814 + Lecanemab + Matching Placebo (E2814) | Eisai | Phase 2/3 | 42 |
| Gantenerumab + Solanezumab + Matching Placebo (Gantenerumab) + Matching Placebo (Solanezumab) | Eli Lilly | Phase 2/3 | 38 |
| Remternetug + Matching Placebo (Remternetug) | Eli Lilly | Phase 2/3 | 45 |
| Remternetug (SC) + Matching Placebo (Remternetug) | Eli Lilly | Phase 2/3 | 45 |
| CNP520 50mg + CNP520 15mg | Novartis | Phase 2/3 | 30 |
| CAD106 Immunotherapy + CNP520 | Novartis | Phase 2/3 | 30 |
| Trontinemab | Roche | Phase 3 | 47 |
| RO7126209 + Placebo | Roche | Phase 1 | 29 |
| RO7126209 + Placebo | Roche | Phase 1/2 | 36 |
| Gantenerumab | Roche | Phase 2/3 | 30 |
| Trontinemab | Roche | Phase 3 | 47 |
| Gantenerumab + Placebo | Roche | Phase 3 | 32 |
| Semaglutide + Placebo | Novo Nordisk | Phase 3 | 40 |
| buntanetap/posiphen + Placebo | Annovis Bio | Phase 3 | 37 |